Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion

Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated a benefit of dapagliflozin to reduce major adverse outcomes in patients with established h...

Descripción completa

Detalles Bibliográficos
Autor principal: Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778368/
https://www.ncbi.nlm.nih.gov/pubmed/31585532
http://dx.doi.org/10.1186/s12933-019-0938-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778368/
https://www.ncbi.nlm.nih.gov/pubmed/31585532
http://dx.doi.org/10.1186/s12933-019-0938-6

Ejemplares similares